Backgrounds: A potential predictive role of 99mTc-MIBI scintigraphy and its possiblerole in monitoring thedisease in patients with multiple myeloma after therapy has been presented only infrequently till now. Design and Subjects: The aim of our study was to evaluate whether 99mTc-MIBI scintigraphy has a predictive value in patients with multiple myeloma and whether it is useful in their follow-up. Twenty-nine patients with multiple myeloma who had undergone two 99mTc-MIBI scintigraphic examinations at least 2 months apart were enrolled in the study. All patients received intensive chemotherapy in the interval between the two scintigraphic studies. Methods andResults: Variations in clinical status and laboratory data guided the decision to permorm a second 99mTc-MIBI scan. Comparison of clinical status and scintigraphic pattems before and after therapy indicative of progressive, improved or stable disease was performed in each patient. Significant correlations were observed between the baseline scintigraphic patterns and clinical status at follow-up in patients evaluated after chemotherapy (X2= 14.5; P=0.001), and also between the scintigraphic examinations and clinical findings, both after therapy (%2= 15.29; P=0.004). Variation in 99mTc-MIBI findings comparing baseline and follow-up evaluations was significantly associated with clinical status (£2 = 23.5; P<0.001). Conclusions: Our results indicate that 99mTc-MIBI scintigraphy could serve both as a prognostic tool and an examination for monitoring the disease in patients with multiple myeloma.

        Key words: multiple myeloma; 99mTc-MIBI scintigraphy; prognostic value; follow-up after therapy